We Will Be Live In:
Uncovering Innovative Strategies for Developing the Next Generation of Peptide-Based Therapeutics
The popularity of peptide therapeutics has increased significantly in recent years. It is estimated that by 2018, the global Peptide therapeutics market is expected to pass $25 billion. This dramatic market increase is driven by both growing incidences of cardiovascular and metabolic diseases, and technological enhancements in peptide synthesis that include high-throughput approaches. Conjugation technologies are also contributing to the growth of peptide therapeutics, and leading to innovative approaches to designing safe and effective therapies.
December’s Peptide Drug Design & Delivery Conference will bring together key decision makers and innovators within this rapidly growing field. This intensive 2-Day program will examine various peptide discovery and synthesis techniques and synthesized and modified peptides. The event will cover peptide engineering, including peptidomimetics and peptide conjugation, as well as cell-penetrating peptides for molecular imaging. Additionally, the event will examine novel strategies for improving peptide properties, including stability and half-life will also be discussed along with novel routes of administration. Case studies will be presented that illustrate the progress made in developing efficacious peptide therapeutics, while leaders in the field point the way to the future for these promising drugs.
Join the industry’s leading drug development executives from numerous leading organizations to discuss and hear unique take-home examples, case studies and multiple peptide drug development and delivery strategies to assist in reducing time-to-market on future drug products.
Benefits of Attending
Program Advisory Board Includes
Waleed Danho, PhD
Former Distinguished Research Leader, Roche
John Nuss, PhD
Vice President, Drug Discovery, Ferring Pharmaceuticals
Ved Srivastava, PhD
Vice President of Chemistry, Intarcia Therapeutics, Inc.
Marian Gindy, PhD
Director, Sterile Product Development, Merck & Co.
Dana Ault-Riche, PhD
Chief Executive Officer, Reflexion Pharmaceuticals
Vladimir Podust, PhD
Director, Analytical Chemistry, Amunix
Who Should Attend
Pharmaceutical, biotech, CRO, diagnostic and academic professionals specializing in:
- Biologics Drug Discovery
- Drug Delivery
- Molecular Biology
- Peptide Development
- Peptide Optimization
- Biologics Research
- Protein Chemistry
- Therapeutics Peptide Chemistry
- Discovery Technology
Download Updated Attendee List
Free Content Downloads
What’s Next for Peptide Product Development?
Sustained Delivery Of Therapeutic Antibodies